• +1-646-491-9876
    • +91-20-67278686

    Search

    Cathepsin K Pipeline Review H2 2017

    Cathepsin K Pipeline Review H2 2017

    • Report Code ID: RW0001884169
    • Category Pharmaceuticals
    • No. of Pages 38
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Pipeline Review, H2 2017

    Summary

    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Cathepsin K or CTSK is an enzyme encoded by CTSK gene. It is closely involved in osteoclastic bone resorption and participates partially in the disorder of bone remodeling. It plays an important role in extracellular matrix degradation. The enzyme is ability to catabolize elastin, collagen, and gelatin allow it to break down bone and cartilage.

    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 3 and 2 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Immunology, Oncology, Central Nervous System, Infectious Disease and Metabolic Disorders which include indications Osteoarthritis, Rheumatoid Arthritis, Bone Cancer, Bone Metastasis, Chagas Disease (American Trypanosomiasis) , Neuropathic Pain and Osteoporosis.

    The latest report Cathepsin K - Pipeline Review, H2 2017, outlays comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)
    - The report reviews Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Overview
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Companies Involved in Therapeutics Development
    Amura Holdings Ltd
    Medivir AB
    Sanofi
    Virobay Inc
    Wroclawskie Centrum Badan EIT+ Sp z oo
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Drug Profiles
    AM-3701 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AM-3876 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MIV-711 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAR-114137 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit CTSK for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VBY-285 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Dormant Products
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Discontinued Products
    Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) - Product Development Milestones
    Featured News & Press Releases
    Jun 09, 2017: Medivir - Enrolment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation to "Go Ahead"
    Feb 01, 2017: MIV-711 Osteoarthritis Trial: Successful fourth independent review of safety data enables trial continuation without any modifications
    Dec 08, 2016: MIV-711 Osteoarthritis Trial: Successful Third Independent Review of Safety Data and Trial Continues Without any Modifications
    Oct 27, 2016: MIV-711 osteoarthritis program: Enrollment in the phase IIa study is complete and independent safety review committee again recommends Go Ahead
    Sep 23, 2016: Medivir: MIV-711 Osteoarthritis Trial: Recommendation to Go Ahead Based on Independent Review of Safety Data, and First Patient Enrolled in Extension Study
    Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis
    Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
    Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders
    May 21, 2013: Medivir Presents Positive Results From Phase Ia Study With MIV-711 For Treatment Of Skeletal Disorders At 2013 ECTS Annual Meeting
    Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders
    May 28, 2012: Medivir Initiates Phase I Clinical Trial Of MIV-711 For Treatment Of Bone Disorders
    Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711
    Sep 16, 2009: Medivir Presented Its Cathepsin K Program at the Ongoing 31st Asbmr Meeting in Denver, USA
    Sep 01, 2009: Medivir Broadens Its Bone Disease Portfolio By Designating One Further Candidate Drug (CD) , MIV-711
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Therapy Areas, H2 2017
    Number of Products under Development by Indication, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Pipeline by Amura Holdings Ltd, H2 2017
    Pipeline by Medivir AB, H2 2017
    Pipeline by Sanofi, H2 2017
    Pipeline by Virobay Inc, H2 2017
    Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H2 2017
    Dormant Projects, H2 2017
    Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Therapy Areas, H2 2017
    Number of Products under Development by Top 10 Indications, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Amura Holdings Ltd
    Medivir AB
    Sanofi
    Virobay Inc
    Wroclawskie Centrum Badan EIT+ Sp z oo

    Request for Sample

    Report Url https://www.reportsweb.com//cathepsin-k-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//cathepsin-k-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//cathepsin-k-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments